JP2024502446A - 癌の治療におけるｋｒａｓ ｇ１２ｃ阻害剤の使用 - Google Patents

癌の治療におけるｋｒａｓ ｇ１２ｃ阻害剤の使用 Download PDF

Info

Publication number
JP2024502446A
JP2024502446A JP2023541058A JP2023541058A JP2024502446A JP 2024502446 A JP2024502446 A JP 2024502446A JP 2023541058 A JP2023541058 A JP 2023541058A JP 2023541058 A JP2023541058 A JP 2023541058A JP 2024502446 A JP2024502446 A JP 2024502446A
Authority
JP
Japan
Prior art keywords
subject
mutation
kras
cancer
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541058A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022150628A5 (https=
JP2024502446A5 (https=
Inventor
アン，アグネス・エル
ヘナリー，ハビー
ンガームチャムナンリー，ガタリー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2024502446A publication Critical patent/JP2024502446A/ja
Publication of JPWO2022150628A5 publication Critical patent/JPWO2022150628A5/ja
Publication of JP2024502446A5 publication Critical patent/JP2024502446A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023541058A 2021-01-08 2022-01-07 癌の治療におけるｋｒａｓ ｇ１２ｃ阻害剤の使用 Pending JP2024502446A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US63/135,449 2021-01-08
US202163189625P 2021-05-17 2021-05-17
US63/189,625 2021-05-17
PCT/US2022/011673 WO2022150628A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Publications (3)

Publication Number Publication Date
JP2024502446A true JP2024502446A (ja) 2024-01-19
JPWO2022150628A5 JPWO2022150628A5 (https=) 2025-01-15
JP2024502446A5 JP2024502446A5 (https=) 2025-01-15

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541058A Pending JP2024502446A (ja) 2021-01-08 2022-01-07 癌の治療におけるｋｒａｓ ｇ１２ｃ阻害剤の使用

Country Status (8)

Country Link
US (1) US20240091230A1 (https=)
EP (2) EP4650006A3 (https=)
JP (1) JP2024502446A (https=)
AU (1) AU2022205969A1 (https=)
CA (1) CA3206523A1 (https=)
MX (1) MX2023007918A (https=)
TW (1) TWI906448B (https=)
WO (1) WO2022150628A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232130A1 (en) * 2019-05-14 2020-11-19 Amgen Inc. Dosing of kras inhibitor for treatment of cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232130A1 (en) * 2019-05-14 2020-11-19 Amgen Inc. Dosing of kras inhibitor for treatment of cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"KRAS G12C Emerges as an Actionable Alteration in NSCLC", ONCLIVEホームページ, [ONLINE], JPN6025051998, 9 November 2020 (2020-11-09), pages 2025 - 12, ISSN: 0005765738 *
CANCER TREATMENT REVIEWS, vol. 89, JPN6025051997, 2020, pages 102070, ISSN: 0005765742 *
MEDICINE, vol. 99, JPN6025051994, 2020, pages 45, ISSN: 0005765740 *
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, vol. Vol.13, Suppl.5, JPN6025051996, 2020, pages 111 - 131, ISSN: 0005765741 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 383, no. 13, JPN6025051993, 2020, pages 1207 - 1217, ISSN: 0005765739 *

Also Published As

Publication number Publication date
EP4650006A3 (en) 2026-01-14
US20240091230A1 (en) 2024-03-21
AU2022205969A1 (en) 2023-07-06
EP4650006A2 (en) 2025-11-19
TW202241442A (zh) 2022-11-01
WO2022150628A1 (en) 2022-07-14
EP4274579A1 (en) 2023-11-15
TWI906448B (zh) 2025-12-01
MX2023007918A (es) 2023-07-13
CA3206523A1 (en) 2022-07-14
AU2022205969A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
Nimeiri et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia
Minor et al. Sunitinib therapy for melanoma patients with KIT mutations
EP4650006A2 (en) Use of a kras g12c inhibitor in treating cancers
TW202207941A (zh) 用於治療癌症之ａｔｒ抑制劑
JP2021502071A (ja) がんバイオマーカーおよびその使用方法
Okines et al. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
US20130252956A1 (en) Methods of treating cancer
JP2016535079A (ja) 核酸生体マーカー及びその使用
CN107750165A (zh) 借助塞里班土单抗的组合治疗
JP2024510612A (ja) ソトラシブ投与レジメン
ES3052701T3 (en) Sotorasib for use in the treatment of cancer
CN103339508A (zh) Agtr1作为贝伐单抗联合疗法的标志物
Sugiyama et al. Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
US20260069593A1 (en) Methods for treating cancer
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
Johnson et al. 8LBA Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
Beyaert et al. Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck
Lochrin et al. Neoadjuvant immunotherapy in resectable non-small cell lung cancer
EP4694891A1 (en) Dosage regimen for sotorasib/carboplatin/pemetrexed in cancer treatment
HK40126893A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
KR20240157061A (ko) 암 치료를 위한 정밀 치료법
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c
TW202529802A (zh) 胃癌和／或胃食管結合部癌的治療
Langer Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260331